Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05478694 Not yet recruiting - Prostate Cancer Clinical Trials

Outcomes of Focal Ablation for Prostate Cancer

Start date: September 2022
Phase: Phase 2
Study type: Interventional

This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

NCT ID: NCT05478239 Not yet recruiting - Prostate Cancer Clinical Trials

ArtemiCoffee in Patients With Rising PSA

Start date: November 2022
Phase: Phase 2
Study type: Interventional

Until now, clinicians have been challenged to improve the treatment of biochemically recurrent (BCR) prostate cancer in which prostatic specific antigen (PSA) rises without radiological or clinical progression years after localized treatment (radical prostatectomy or radiation therapy) with or without hormonal treatment. Approximately 50-90% of men with high-risk prostate cancer will experience a BCR. Artesunate has demonstrated anti-tumor activity in both in vivo and in vitro cell lines. It is hypothesized that Artemisia annua (Aa) coffee has the potential to decrease rising PSA among patients with biochemical recurrence of prostate cancer.

NCT ID: NCT05477823 Not yet recruiting - Prostate Cancer Clinical Trials

Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

Start date: August 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate the imaging and gene expression biomarkers in prostate cancer. Participants have high-risk prostate cancer and have indicated they will undergo external beam radiation therapy, brachytherapy, and androgen deprivation therapy (EBRT+BTX+ADT). Participants can expect to be in this study for up to 5 years.

NCT ID: NCT05472532 Not yet recruiting - Breast Cancer Clinical Trials

Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)

INOVOLINE
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

A variety of in vivo experimental models have been established for the studies of human cancer using both cancer cell lines and patient-derived xenografts (PDXs). In order to meet the aspiration of precision medicine, the in vivo murine models have been widely adopted. However, common constraints such as high cost, long duration of experiments, and low engraftment efficiency remained to be resolved. The chick embryo chorioallantoic membrane (CAM) is an alternative model to overcome some of these limitations. The chick CAM is shown to be a robust model for both the inoculation of cell lines and grafting of patient tumors for drug therapy evaluations and target genes/pathways analysis. The start-up INOVOTION has developed a unique, highly sensitive and reproducible CAM assay to graft human cancer cells/tumors in the chicken egg environment. INOVOTION's technology was validated for over 55 human tumor cell lines, including carcinomas, gliomas and melanomas, as well as over 30 reference drugs currently on the market. At INOVOTION, the graft of human cancer cells on the chicken CAM is currently conducted manually. To scale-up, the process was recently automated. The automation performance was assessed on cancer cells lines. The objective of this study is to demonstrate that the automation of the INOVOTION process enables tumors' proliferation using patient samples (from tumor samples or circulating tumor cells) as grafting material.

NCT ID: NCT05471414 Not yet recruiting - Prostate Cancer Clinical Trials

IIT Whole-Food Plant-Based Diet (WFPBD)

WFPBD
Start date: July 2022
Phase: N/A
Study type: Interventional

The study is comparing the effect on weight of providing home-delivered whole-food, plant-based meals versus standard, general nutritional counseling to men with prostate cancer on androgen-deprivation therapy (ADT).

NCT ID: NCT05471128 Not yet recruiting - Prostate Cancer Clinical Trials

MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy

Start date: November 2022
Phase:
Study type: Observational

The purpose of this study is to find out how best to detect clinically significant lesions of prostate cancer by using micro-ultrasound technology (ExactVu) and by multiparametric magnetic-resonance imaging (mpMRI).

NCT ID: NCT05470036 Not yet recruiting - Prostate Cancer Clinical Trials

Improving Germline Testing in At-Risk Patients With Prostate Cancer

IMPRINT
Start date: August 2022
Phase: N/A
Study type: Interventional

A quality improvement initiative to improve rates of germline testing among men with prostate cancer through the use of an in-clinic educational session.

NCT ID: NCT05469269 Not yet recruiting - Prostate Cancer Clinical Trials

Cleveland African American Prostate Cancer Project

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this research is to test intervention strategies that encourage and support Black or African American men who are 40 and older to complete prostate cancer screening, and specifically to complete a prostate-specific antigen (PSA) test.

NCT ID: NCT05467176 Not yet recruiting - Prostate Cancer Clinical Trials

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

OPTYX
Start date: August 31, 2022
Phase:
Study type: Observational

This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.

NCT ID: NCT05462392 Not yet recruiting - Prostate Cancer Clinical Trials

Robot-assisted Urological Surgeries Using the MicroHand S Robot

Start date: July 2022
Phase: N/A
Study type: Interventional

A single-blinded, prospective randomized parallel controlled clinical trial is designed and will be conducted from July 2022 to November 2023 (anticipated). One hundred and thirty-six patients (anticipated) with renal cancer or bladder cancer or prostate cancer will be enrolled in this study. Those patients will be enrolled by two hospital centers and the patients will be randomly divided into the Micro Hand S surgical robot group and the da Vinci surgical robot group. Robot-assisted partial nephrectomy, radical cystectomy, and radical prostatectomy will be conducted using the Micro Hand S robot or the da Vinci robot. The success rate of operation, assembly time, operation time, intraoperative hemorrhage, continence rate (if applicable), postoperative pain, comprehensive complication index, resident time and surgeon satisfaction were recorded. The aim of the study is to determine whether the newly developed Chinese Micro Hand S surgical robot results in non-inferiority outcomes in urological surgeries compared with the prevalent da Vinci robot.